Explore

Rapid Read Rapid Read
HSS Study Highlights Efficacy of Non-Opioid Pain Relief in Orthopedic Surgery

HSS Study Highlights Efficacy of Non-Opioid Pain Relief in Orthopedic Surgery

A study conducted by the Hospital for Special Surgery (HSS) has evaluated the effectiveness of a new non-opioid pain reliever, suzetrigine, in postoperative orthopedic surgery patients. The medication, approved by the FDA in January 2025, targets pain signals on nerves outside the brain, offering a novel approach to pain management. The study involved 103 patients, with 92.2% tolerating the drug well. Suzetrigine presents a promising alternative to opioids, particularly for patients with contraindications to opioid use. The research is part of HSS's ongoing efforts to advance non-opioid pain management options and improve patient outcomes.
Trendline Trendline
Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted Therapeutic for IBD

Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted Therapeutic for IBD

Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted Therapeutic for IBD
Trendline Trendline
Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted IL-22 Therapeutic

Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted IL-22 Therapeutic

Ampersand Biomedicines Unveils Preclinical Data on Gut-Targeted IL-22 Therapeutic
Trendline Trendline
Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings

Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings

Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings
Trendline Trendline
Eluciderm, Inc. Receives Industrial R Award for ELU42's Wound Healing Research

Eluciderm, Inc. Receives Industrial R Award for ELU42's Wound Healing Research

Eluciderm, Inc. Receives Industrial R Award for ELU42's Wound Healing Research
Trendline Trendline
Novo Nordisk's Etavopivat Shows Promise in Sickle Cell Disease, Pressures Competitors

Novo Nordisk's Etavopivat Shows Promise in Sickle Cell Disease, Pressures Competitors

Novo Nordisk's Etavopivat Shows Promise in Sickle Cell Disease, Pressures Competitors
Rapid Read Rapid Read
Utah's AI Prescription Refill Program Sparks Debate Over Healthcare Innovation

Utah's AI Prescription Refill Program Sparks Debate Over Healthcare Innovation

Utah has launched a pilot program allowing an AI system, developed by Doctronic, to refill prescriptions for certain medications. The AI, designed to replicate a physician's decision-making process, handles refills for about 190 low-risk medications, excluding opioids and injectables. The system verifies patient residency, checks for drug interactions, and assesses medication adherence. If issues arise, a Doctronic physician is available for consultation. The program aims to improve access to care and reduce costs, though it raises ethical and regulatory concerns.
Trendline Trendline
Orsini Becomes Exclusive Partner for Denali Therapeutics' AVLAYAH, Enhancing Rare Disease Treatment

Orsini Becomes Exclusive Partner for Denali Therapeutics' AVLAYAH, Enhancing Rare Disease Treatment

Orsini Becomes Exclusive Partner for Denali Therapeutics' AVLAYAH, Enhancing Rare Disease Treatment
Trendline Trendline
AstraZeneca's Tozorakimab Shows Promise in COPD Treatment with Positive Phase 3 Trial Results

AstraZeneca's Tozorakimab Shows Promise in COPD Treatment with Positive Phase 3 Trial Results

AstraZeneca's Tozorakimab Shows Promise in COPD Treatment with Positive Phase 3 Trial Results
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Trendline Trendline
AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry

AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry

AstraZeneca's Tozorakimab Shows Promise in COPD Phase 3 Trials, Paving Way for Market Entry
Rapid Read Rapid Read
New Anti-Clotting Drug Asundexian Shows Promise in Reducing Stroke Risk

New Anti-Clotting Drug Asundexian Shows Promise in Reducing Stroke Risk

A recent phase III trial has revealed that the investigational anti-clotting drug Asundexian, developed by Bayer, significantly reduces the risk of stroke by 26% without increasing the risk of major bleeding. The trial, involving 12,327 adult patients from 37 countries, focused on individuals who had experienced a non-cardioembolic stroke or transient ischaemic attack. Participants were administered Asundexian alongside standard antiplatelet therapy, such as aspirin. The results showed a notable reduction in ischemic strokes and major cardiovascular events among those taking the drug compared to a placebo group. The trial's principal investigator, Mike Sharma, emphasized the potential of Asundexian in providing safer long-term stroke prevention.